179 related articles for article (PubMed ID: 35372578)
1. Assessment of the Concentration of Endogenous Factors Regulating Angiogenesis, VASH-1 and VEGF-A, in the Blood Serum of Patients with Neuroendocrine Neoplasms.
Strzelczyk J; Wójcik-Giertuga M; Cuber P; Biernacki K; Kos-Kudła B; Strzelczyk JK
Biomed Res Int; 2022; 2022():9084393. PubMed ID: 35372578
[TBL] [Abstract][Full Text] [Related]
2. Angiogenic factors as prognostic markers in neuroendocrine neoplasms.
Puliani G; Sesti F; Anastasi E; Verrico M; Tarsitano MG; Feola T; Campolo F; Di Gioia CRT; Venneri MA; Angeloni A; Appetecchia M; Lenzi A; Isidori AM; Faggiano A; Giannetta E;
Endocrine; 2022 Apr; 76(1):208-217. PubMed ID: 35088292
[TBL] [Abstract][Full Text] [Related]
3. Is determination of matrix metalloproteinases and their tissue inhibitors serum concentrations useful in patients with gastroenteropancreatic and bronchopulmonary neuroendocrine neoplasms?
Blicharz-Dorniak J; Kos-Kudła B; Foltyn W; Kajdaniuk D; Marek B; Zemczak A; Strzelczyk J
Endokrynol Pol; 2012; 63(6):470-6. PubMed ID: 23339005
[TBL] [Abstract][Full Text] [Related]
4. The Correlation Between [
Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z
Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
6. Plasma vasohibin-1 and vasohibin-2 are useful biomarkers in patients with esophageal squamous cell carcinoma.
Yamamoto M; Ozawa S; Ninomiya Y; Koyanagi K; Oguma J; Kazuno A; Hara H; Yatabe K; Kajiwara H; Nakamura N; Sato Y
Esophagus; 2020 Jul; 17(3):289-297. PubMed ID: 31980976
[TBL] [Abstract][Full Text] [Related]
7. The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Pancreatic Neuroendocrine Neoplasms (p-NENs).
Kolasińska-Ćwikła AD; Konsek SJ; Buscombe JR; Maciejkiewicz K; Cichocki A; Roszkowska-Purska K; Sawicki Ł; Tenderenda M; Cwikla JB
Nucl Med Rev Cent East Eur; 2019; 22(1):1-7. PubMed ID: 30276787
[TBL] [Abstract][Full Text] [Related]
8. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
[TBL] [Abstract][Full Text] [Related]
9. Expression levels of serum vasohibin-1 and other biomarkers in type 2 diabetes mellitus patients with different urinary albumin to creatinine ratios.
Ren H; Shao Y; Ma X; Yang M; Liu Y; Wang Q
J Diabetes Complications; 2019 Jul; 33(7):477-484. PubMed ID: 31097304
[TBL] [Abstract][Full Text] [Related]
10. Assessment of VEGF and VEGF R1 serum levels in patients with neuroendocrine neoplasms before and after treatment with first-generation somatostatin analogues.
Rosiek V; Janas K
Endokrynol Pol; 2022; 73(3):612-618. PubMed ID: 36059176
[TBL] [Abstract][Full Text] [Related]
11. [Consensus and controversy on subtype classification of gastric neuroendocrine neoplasms].
Tan H
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):977-981. PubMed ID: 28900986
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations.
Abdel-Rahman O
Tumour Biol; 2014 Nov; 35(11):10615-25. PubMed ID: 25230786
[TBL] [Abstract][Full Text] [Related]
13. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis and vascular maturation in neuroendocrine tumors.
Yazdani S; Kasajima A; Tamaki K; Nakamura Y; Fujishima F; Ohtsuka H; Motoi F; Unno M; Watanabe M; Sato Y; Sasano H
Hum Pathol; 2014 Apr; 45(4):866-74. PubMed ID: 24656098
[TBL] [Abstract][Full Text] [Related]
15. Alteration of the immunophenotype and cytokine profiles in patients affected by neuroendocrine neoplasms.
Boemi I; Piccini S; Colombo FS; Smiroldo V; Zerbi A; Capretti G; Alloisio M; Trivellin G; Lavezzi E; Mazziotti G; Vitali E; Lania AG
Endocrine; 2024 Mar; 83(3):810-823. PubMed ID: 37845576
[TBL] [Abstract][Full Text] [Related]
16. [Assessment of pro- and antiangiogenic factors blood serum concentrations in patients with hormonal inactive adrenal tumors].
Korzeniewska M; Kołomecki K; Stepień H; Naze M; Stepień T; Kuzdak K
Endokrynol Pol; 2005; 56(1):39-44. PubMed ID: 16335673
[TBL] [Abstract][Full Text] [Related]
17. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
Masui T; Ito T; Komoto I; Uemoto S;
BMC Cancer; 2020 Nov; 20(1):1104. PubMed ID: 33189127
[TBL] [Abstract][Full Text] [Related]
18. Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm.
Wang Y; Chen Y; Li X; Hu W; Zhang Y; Chen L; Chen M; Chen J
BMC Cancer; 2018 Jun; 18(1):691. PubMed ID: 29940892
[TBL] [Abstract][Full Text] [Related]
19. Results of a prospective multicenter neuroendocrine tumor registry reporting on clinicopathologic characteristics of Greek patients.
Nikou GC; Pazaitou-Panayiotou K; Dimitroulopoulos D; Alexandrakis G; Papakostas P; Vaslamatzis M; Kaldrymidis P; Markussis V; Koumarianou A;
BMC Endocr Disord; 2016 Feb; 16():8. PubMed ID: 26872616
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
